Article Sidebar

PDF
Date Published: 13/03/2022
Abstract Views: 242
Views PDF: 72
DOI: https://doi.org/10.51298/vmj.v510i2.1988
Issue
Vol. 510 No. 2 (2022)
Section
Các bài báo
How to Cite
Tấn, Đỗ ., & Đỗ Ngọc Hiên, N. . (2022). THE OUTCOME OF LASER THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY. Vietnam Medical Journal, 510(2). https://doi.org/10.51298/vmj.v510i2.1988

THE OUTCOME OF LASER THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY

Đỗ Tấn1, Nguyễn Đỗ Ngọc Hiên2,
1 Central Eye Hospital
2 Hanoi Medical University

Main Article Content

Abstract

Purpose: To evaluate the treatment outcome of laser for polypoidal choroidal vasculopathy (PCV). Methods: Prospective non-controlled interventional study on patients diagnosed with extrafoveal and peripapillary PCV who were treated and followed at Vitreous-Retinal Deparment, National eye hospital, from 10/2013 to 02/2020. Results: Laser was performed for 30 patients (32 eyes) of those PCV located at peripheral, extrafoveal and peripapillary area. Patients ranged in age from 45 to 70 years with a mean of 59,23 ± 7,53; included 16 male (53,33%) and 14 female (46,67%). Mean visual acuity markedly increased from 1,03 at baseline to 0,78 logMAR at the 6th month (with p < 0,01). Central foveal thickness decreased from 290 µm to the normal level 232,81 µm at the 6th month (p <0,01). We noted good outcome in 20 eyes (62,5%), average outcome in 7 (21,9%) and poor outome in 5 cases (15,6%). Overall success was on majority 27/42 eyes (84,4%). Conclusion: Laser is a good safe therapeutic modality for extrafoveal and peripapillary PCV.

Article Details

Keywords

laser on polypoidal choroidal vasculopathy, laser

References

1. Ciardella A.P., Donsoff I.M., Huang S.J., et al. (2004). Polypoidal choroidal vasculopathy. Surv Ophthalmol, 49(1), 25–37.
2. Ho C.P.S. and Lai T.Y.Y. (2018). Current management strategy of polypoidal choroidal vasculopathy. Indian J Ophthalmol, 66(12), 1727–1735.
3. Gemmy Cheung C.M., Yeo I., Li X., et al. (2013). Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy. Am J Ophthalmol, 155(2), 295-304.e1.
4. Koh A., Lee W.K., Chen L.-J., et al. (2012). EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina Phila Pa, 32(8), 1453–1464.
5. Kwok A.K.H., Lai T.Y.Y., Chan C.W.N., et al. (2002). Polypoidal choroidal vasculopathy in Chinese patients. Br J Ophthalmol, 86(8), 892–897.
6. Lee M.-W., Yeo I., Wong D., et al. (2009). Argon laser photocoagulation for the treatment of polypoidal choroidal vasculopathy. Eye Lond Engl, 23(1), 145–148.
7. Anantharaman G., Sheth J., Bhende M., et al. (2018). Polypoidal choroidal vasculopathy: Pearls in diagnosis and management. Indian J Ophthalmol, 66(7), 896–908.
8. Vilaplana D., Castilla M., and Poposki V. (2005). Laser photocoagulation in idiopathic polypoidal choroidal vasculopathy. Over one year follow-up. Arch Soc Espanola Oftalmol, 80(10), 597–602.